Some people with psoriasis can also develop psoriatic arthritis, when the immune system attacks the joints as well, causing inflammation. Like psoriasis, psoriatic arthritis symptoms flare and subside, vary from person to person, and even change locations in the same person over time. Psoriatic arthritis can affect any joint in the body, and it may affect just one joint, several joints or multiple joints. For example, it may affect one or both knees. This issue will include articles on Genetic and Epigenetic aspects of psoriatic arthritis, Clinical features and diagnostic considerations in psoriatic arthritis, Natural history, prognosis and socioeconomic aspects of psoriatic arthritis, Etiology and pathogenesis of psoriasis and many more!

This issue is devoted to patient reported outcomes and their impact in the study of rheumatic diseases and the authors will also discuss PROs and vulnerable populations with rheumatic disease; technology, electronic health records and PROs: past, present and future; the promise of PROMIS – a uniform approach to PROs across rheumatic diseases, quality measures and PROs and how they relate and the importance of PROs in delivering quality care in the rheumatic diseases, and many more exciting articles.

In this issue of Rheumatic Disease Clinics, guest editor Brian F. Mandell brings his considerable expertise to the topic of Rheumatology pearls for the primary care physician. - Provides in-depth reviews on the latest updates in Rheumatology pearls for the primary care physician, providing actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field; Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.

This issue of Rheumatic Disease Clinics, guest edited by Drs. Xenofon Baraliakos and Michael H. Weisman, Spondyloarthritis: The Changing Landscape Today, takes a very comprehensive look at all of the essential topics surrounding spondyloarthritis. This issue is one of four selected each year by Dr. Weisman, who is also our series consulting editor. This very comprehensive issue will include the following topics (among others): Molecular biology approaches to understanding SpA; Microbiome and its role in SpA; Classification criteria in axSpA; Administrative data and coding for axSpA; Approach to the patient with IBD and AxSpA; Axial PsA vs. Axial SpA with Psoriasis; Emerging imaging techniques in SpA; The future of imaging in axSpA; Treatment Recommendations vs. Treat to Target in axSpA; The future of axSpA treatmentAxSpA in the era of Precision Medicine; Quality of Life as an outcome in studies of axSpA; Gender differences in SpA; The patient's perspective on the burden of disease in axSpA; and Juvenile SpA.

This issue of Rheumatic Disease Clinics, guest edited by Dr. Alfred Kim and Zahi Touma, will discuss a number of key topics surrounding Lupus. This issue is one of four selected each year by series Consulting Editor, Dr. Michael Weisman. Topics discussed in this issue include, but are not limited to: Interferons in SLE, NETosis and neutrophils in SLE, AMP update in lupus nephritis, Patient-reported outcomes, Complement, T cells in SLE, B cells in SLE, Outcome measures for SLE clinical trials, Mitochondrial physiology in SLE, Pregnancy, Lupus cohorts, Innovative trials and new opportunities in SLE, Classification and diagnosis of SLE, and Updates on SLE Treatment.

Written by experts in the dermatology field, this new fourth edition of Moderate-to-Severe Psoriasis discusses the current use of biologics and other pharmacologic and phototherapy treatments for moderate-to-severe psoriasis. Illustrated with high quality color figures, this standalone text emphasizes safe and effective treatments for the psoriasis

Edited by Drs. Jack Cush and Kathryn Dao, this issue of Rheumatic Disease Clinics of North America addresses one of the most significant issues facing the rheumatologist today––drug safety in a changing world where rheumatoid arthritis (RA) severity is less, patients are being identified and treated at a very early stage, and prevention is on the horizon. Topics covered include: communicating the risk of side effects, urate-lowering therapies, biphosphonates, biologics, malignancy risks, and administering therapies to patients with co-morbidities.